MolDX Technical Assessment: What Labs Must Submit for Medicare Coverage
Short answer: A MolDX Technical Assessment is Palmetto GBA's pre-claim review of whether a molecular test is reasonable and necessary for Medicare. Labs submit a dossier showing analytical validity, clinical validity and clinical utility. The outcome is full coverage, limited coverage or non-coverage. Veracyte's Prosigna test, covered effective August 19, 2026, is the latest example.
On October 16, 2026, Veracyte announced that its Prosigna Breast Risk of Recurrence test had received coverage for its Technical Assessment submission through Palmetto GBA's MolDX program, effective August 19, 2026. According to the company release, coverage applies to postmenopausal women with early-stage estrogen receptor positive breast cancer who meet applicable Medicare criteria, including stage I or II disease with 0 to 3 positive lymph nodes. Prosigna launched in the U.S. in June 2026 as a laboratory-developed test run in the company's CLIA-certified laboratory in San Diego.
The announcement is a useful prompt for any molecular lab. Most clinical and billing leaders know MolDX exists, but fewer can describe what a Technical Assessment actually demands, what it decides, and what has to happen to claims while it is pending. This article walks through the published requirements. It is decision support for lab, compliance and revenue cycle leaders, not coverage advice for a specific test.
What a Technical Assessment is, and when it applies
The MolDX Molecular Diagnostic Tests local coverage determination, L35025, states that MolDX reviews all new test clinical information to decide whether a test meets Medicare's reasonable and necessary standard. The same LCD says labs must submit a comprehensive dossier on each new test or assay before claim submission, and that MolDX covers and pays only for tests that demonstrate analytical validity, clinical validity and clinical utility.
The Palmetto GBA MolDX Manual (M00106) adds the scope. In the version we reviewed, version 26.0 from December 2019, a Technical Assessment is required for molecular assays that are laboratory developed tests, use new or novel technology, or have undefined or unproven clinical utility. The manual notes that FDA-approved tests with proven utility, used only within labeled indications, may be exempt. Because the manual we reviewed is dated, labs should confirm the current version with the program before relying on any step described here.
What goes in the dossier
The manual lists the dossier contents in a table. They include an executive summary describing the assay, intended patient populations and intended purpose; a Technical Assessment Summary Form (M00116) for all platforms except next-generation sequencing; an additional analytical performance specification document for comprehensive genomic profiling NGS assays (M00018); a separate one for circulating tumor DNA assays (M00135); clinical utility studies; clinical validity studies; analytic validity materials; and economic value studies.
The line that trips up early-stage companies is the evidence standard. The manual states that clinical utility studies must be completed, published work, and that abstracts and unpublished studies are not accepted. A lab that is relying on a conference poster or an internal validation report to demonstrate utility should expect that to fall short. The manual also says CMS has directed MolDX to apply the CDC's ACCE criteria, with subject matter experts and the MolDX team assessing whether the test meets the reasonable and necessary standard.
The pathway, step by step
The sequence is simple on paper, and the operational risk sits in step three. First, the lab submits the dossier before it bills. Second, MolDX and its experts review it. Third, the lab holds claims: Section 2.2 of the manual says claims for the service should be suspended during the review period to avoid denial. Fourth, MolDX issues a decision.
The manual lists three possible outcomes: full coverage, with pricing review starting after an LCD is drafted; limited coverage; or non-coverage if the test does not meet Medicare's reasonable and necessary criteria. An LCD may be developed when a test needs limitations, and results are published to providers. For a lab, that means a favorable decision does not instantly produce a payment rate. Pricing is a separate step after coverage.
The manual we reviewed does not state a Technical Assessment fee or a review timeline. The only timelines it gives concern related processes, such as a 30-day window to decide whether a reconsideration request for an excluded test is valid and a decision within 90 days of a valid request. Any planning assumption about total elapsed time should therefore come from the program directly, not from this article. For one dated third-party data point, see our piece on CPT 81479 unlisted molecular code denials, which cites a 2023 XiFin description of multi-month initial responses.
Reading the Prosigna announcement carefully
Two details in the announcement are easy to conflate. The Veracyte release cites LCD L36125, "MolDX Breast Cancer Assay Prosigna," as the governing policy. The CMS Medicare Coverage Database lists that Palmetto LCD with an original effective date of April 22, 2021, so the policy itself is not new. What the release describes as effective August 19, 2026 is coverage of the company's Technical Assessment submission. Our reading, which the release does not spell out, is that the LCD defines the test class while the Technical Assessment decision determines whether a particular lab's version of the test is covered. Labs should not assume that a published LCD for a test name means their own assay is covered.
Using the release's own dates, the interval from the August 19 effective date to the October 16 announcement is 58 days, which is our arithmetic. That gap is a reminder that coverage effective dates and public awareness can diverge. Billing teams generally learn of coverage from the program's published coverage lists and contractor notices, not from press releases.
How a decision spreads across contractors
MolDX policies are published by multiple Medicare Administrative Contractors. A search of the Medicare Coverage Database for Prosigna returns matching "MolDX: Breast Cancer Assay: Prosigna" LCDs for Palmetto GBA (L36125), WPS (L36811), Noridian (L36380) and CGS (L36425), with effective dates ranging from 2021 to March 2026. A fifth, Noridian L36386, shows a retirement date of January 22, 2026; Noridian L36380 took effect that same day.
The practical point is that a lab with a covered test still has to confirm the policy applies in each contractor jurisdiction where it bills, and has to track each contractor's version and effective date. If your claims also depend on identifier registration, review our guide to DEX Z-codes and genetic testing claims. Note that LCD L35025, in the version we reviewed, says each claim must carry a test-specific identifier, while its revision history records that Z-code application references were removed in 2016 and a DEX registration requirement was removed in 2019. Confirm the current identifier mechanics before building billing rules.
A pre-submission checklist for lab leaders
These steps are general operating practice, not program requirements.
Inventory your evidence. Map each claim you make about the assay to a published study. Under the manual's standard, abstracts and unpublished data do not count toward clinical utility.
Match the dossier to the platform. Decide early whether the NGS or ctDNA add-on documents apply, since they are required in addition to the summary form.
Plan the claim hold. Decide how claims will be held, tracked and released, and who owns that queue, so revenue is delayed rather than denied. See also our overview of genetic testing denials.
Follow developer indications. LCD L35025 says MolDX expects laboratory providers to follow test indications published by the developer, so your ordering and billing criteria should mirror them.
Track policies by contractor. Maintain a register of LCD numbers, versions and effective dates per jurisdiction, and cross-check against Medicare coverage for genetic testing as part of onboarding a new assay.
Frequently asked questions
What is a MolDX Technical Assessment?
It is the pre-claim review MolDX uses to decide whether a molecular test meets Medicare's reasonable and necessary standard. Labs submit a dossier covering analytical validity, clinical validity and clinical utility, and MolDX issues a coverage decision that can be full, limited or non-coverage.
Which tests need one?
Per the MolDX Manual version we reviewed, a Technical Assessment applies to molecular assays that are laboratory developed tests, use new or novel technology, or have undefined or unproven clinical utility. FDA-approved tests used within labeling with proven utility may be exempt. Confirm current scope with the program.
Can we bill while the review is pending?
The manual says to suspend claims during the review period to avoid denial, and LCD L35025 says the dossier must be submitted before claim submission. Labs should hold claims for the service and track them, rather than submit and expect to appeal later. Confirm current instructions with the contractor.
Are abstracts enough to prove clinical utility?
No. The manual's dossier table states that clinical utility studies must be completed, published work and that abstracts and unpublished studies are not accepted. Labs should build the evidence package around peer-reviewed publications and treat posters, preprints and internal reports as supporting material only.
Does a published LCD mean my version of the test is covered?
Not necessarily. An LCD can describe a test class, while coverage of a specific lab's assay follows that lab's own Technical Assessment outcome. Veracyte's Prosigna coverage, effective August 19, 2026, followed its submission even though LCD L36125 dates to 2021. Verify the status of your own assay.
For workflow tooling that helps teams track payer policies and documentation before submission, visit the ScreenMyGene homepage.
Educational disclaimer: This article is for general educational and informational purposes only. It is not legal, coding, billing, compliance or medical advice, and it does not guarantee coverage or payment. Program requirements change; confirm current rules with Palmetto GBA MolDX or the relevant Medicare Administrative Contractor and consult qualified counsel or certified coders for specific decisions.
Sources: Veracyte, Inc., "Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test," GlobeNewswire (Oct 16, 2026); CMS Medicare Coverage Database, LCD L35025 "MolDX: Molecular Diagnostic Tests (MDT)" and LCDs L36125, L36425, L36380, L36811, L36386 (queried Nov 1, 2026); Palmetto GBA, MolDX Coverage, Coding, and Pricing Standards and Requirements (M00106), Version 26.0 (Dec 2019).